Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Zymeworks reports after market close, meaning Day 0 reflects anticipatory trading before results are known, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action shows significant volatility around earnings releases, with an average absolute Day +1 move of 4.54% and Day +1 range of 8.96%. The most recent report on May 7, 2026 triggered a sharp -10.19% decline the following day after the company missed estimates badly, demonstrating how severely the market punishes execution failures. Earlier reports in 2025 showed more muted reactions, with Day +1 moves ranging from -8.04% to +4.89%, but the trend has been toward larger negative moves as misses have mounted. Investors should expect material price movement tomorrow — the stock rarely trades quietly after earnings, and given the recent pattern of disappointing results, downside risk appears elevated if ZYME fails to meet or beat the $-0.50 consensus.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 4.88% through the August 21 expiration, which sits slightly above the historical Day 0 average of 1.84% but materially below the Day +1 average move of 4.54%. This suggests options traders are anticipating a meaningful but not extreme reaction, though recent history shows ZYME is capable of moves well beyond this range when results significantly deviate from expectations.

Part 3: What Analysts Are Saying

Analyst sentiment remains overwhelmingly bullish despite recent operational stumbles, with 12 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings — translating to an average recommendation of 4.85 out of 5.0. The consensus price target of $39.25 implies 67% upside from the current $23.50 price, with a range spanning from $31.00 (32% upside) to $58.00 (147% upside).

The rating distribution has remained unchanged over the past month, indicating analysts are maintaining conviction in the long-term thesis despite near-term execution challenges. This stability suggests the Street views recent misses as timing issues related to milestone payments rather than fundamental problems with the pipeline or partnership strategy. The single Hold rating provides a modest counterweight to the otherwise unanimous bullishness, but the overwhelming concentration of Strong Buy ratings reflects confidence that ZYME's ADC platform and bispecific programs will ultimately deliver value.

The wide range in price targets — spanning $27 from low to high — reveals meaningful disagreement about the pace and probability of clinical and commercial success. Bulls at the high end are pricing in successful trial readouts and expanded partnerships, while more conservative analysts appear focused on nearer-term cash flow challenges and the need to demonstrate consistent revenue generation.

Part 4: Technical Picture

The Barchart Technical Opinion has deteriorated sharply heading into earnings, currently showing a 72% Sell signal — a dramatic reversal from the 72% Buy signal just one month ago and a significant weakening from last week's 40% Sell. This rapid shift reflects mounting technical pressure as the stock has failed to hold key support levels.

Timeframe Analysis:

• Short-term (100% Sell): Maximum bearish signal indicates severe near-term downside momentum heading into the report
• Medium-term (50% Sell): Moderate sell signal suggests intermediate-term trend has turned negative but hasn't reached extreme oversold levels
• Long-term (50% Sell): Moderate sell signal reflects deterioration in the longer-term trend structure

Trend Characteristics: The current environment shows Weak strength with Average direction, suggesting the downtrend lacks conviction but remains intact — a setup that could amplify volatility around earnings as the stock searches for a catalyst to reverse momentum or confirm further weakness.

ZYME is trading at $23.50, positioned below its 20-day ($23.66), 50-day ($24.09), 100-day ($24.90), and 200-day ($24.05) moving averages but above its 5-day ($22.55) and 10-day ($22.64) averages. This configuration shows the stock has stabilized in the very short term after recent selling but remains in a confirmed downtrend across all meaningful timeframes. The 200-day average at $24.05 now represents immediate overhead resistance, while the 50-day at $24.09 marks a critical level that must be reclaimed to signal any meaningful technical recovery. The overall setup is cautionary heading into earnings — the stock is technically weak, sentiment has turned decisively negative, and the burden is on management to deliver a significant positive surprise to reverse the technical damage. Any disappointment risks accelerating the downtrend toward the $22 level, while a strong beat could trigger a sharp short-covering rally back toward the $25-26 resistance zone.